双次自体造血干细胞移植治疗T细胞非霍奇金淋巴瘤疗效观察

肖方; 刘利; 郝淼旺; 张静宜; 陈任安; 梁英民

doi:10.13201/j.issn.1004-2806.2012.04.007

双次自体造血干细胞移植治疗T细胞非霍奇金淋巴瘤疗效观察

- 第四军医大学唐都医院血液内科(西安, 710038)

详细信息

通讯作者: 梁英民,E-mail:liangym@fmmu.edu.cn

中图分类号: R733.1

收稿日期: 2011-08-01

修回日期: 2011-12-07

Double autologous hematopoietic stem cell transplantation for T cell non-Hodgkin’s lymphoma

- Department of Hematology, Tangdu Hospital, Fouth Military Medical University, Xi'an, 710038, China

More Information

Corresponding author: LIANG Yingmin, E-mail: liangym@fmmu.edu.cn

Received Date: 01 August 2011

Revised Date: 07 December 2011

摘要

摘要: 目的:评价自体造血干细胞移植治疗T细胞非霍奇金淋巴瘤的临床疗效及安全性。方法:回顾性分析T细胞非霍奇金淋巴瘤28例患者的资料,其中单次移植5例,双次移植23例。第1次移植预处理方案分别为:IEP方案19例,MiFAP方案9例。第2次移植预处理方案分别为:IEP方案9例,MiFAP方案14例。2次移植间隔为8(6~10)周。结果:所有患者均获得造血功能重建。无一例移植相关死亡。随访至2011年2月1日,中位随访时间28(2~98)个月。复发8例,经治疗无效均于复发后1~6个月死亡。5例单次移植患者复发3例(60%),23例双次移植患者复发5例(21.7%)。23例双次移植患者1年、3年预期生存率分别为95.7%和76.1%,1年、3年预期无进展生存率分别为95.7%和71.5%。23例双次移植患者预期中位无进展生存时间60个月,5例单次移植患者预期中位无进展生存时间18个月。结论:双次移植对预后不良、化疗效果欠佳的T细胞非霍奇金淋巴瘤疗效良好,安全性好。
- 淋巴瘤,非霍奇金 /
- 造血干细胞移植 /
- 预处理方案
Abstract: Objective:To evaluate the clinical efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT) for the aggressive T cell non-Hodgkin's lymphoma (T-NHL). Method:We reported and analyzed 28 patients with aggressive T-NHL retrospectively. The first conditioning regimen was 19 of IEP and 9 of MiFAP. Twenty-three patients received the second AHSCT in 6-8 weeks after the first AHSCT.The conditioning regimen was 9 of IEP and 14 of MiFAP. Result:All engrafted patients had rapid hematopoietic reconstitution. There was no AHSCT related death. All patients were followed-up to February 1st,2011. The median follow-up duration was 28 (2-98) months. Eight patients relapsed and then died in 1-6 months,of which 3 had received single AHSCT (SASHCT),and 5 had received double AHSCT (DASHCT). Among 23 patients who had received DASHCT,the 1 and 3 years overall survival (OS) was 95.7% and 76.1%,while the 1 and 3 years progression free survival (PFS) was 95.7% and 71.5%,respectively. Median DFS time was 60 months for the DAHSCT group and was 18 months for the SAHSCT group. Conclusion:DASHCT in tandem for aggressive T cell lymphoma is probably safe and effective.
- lymphoma,non-Hodgkin’s /
- hematopoietic stem cell transplantation /
- conditioning regimen

HTML全文

参考文献(14)

[1]	The Non-Hodgkin lymphoma classification project.A clinical evaluation of the international lymphoma study group classification of Non-Hodgkin lymphoma[J].Blood,1997,89: 3909-3918.
[2]	[KG*1]候军,章卫平,邱慧颖,等.自体外周血干细胞移植治疗T细胞淋巴瘤的临床研究[J].临床肿瘤学杂志,2009,14(2):102-105.
[3]	[KG*1]MOUNIER N,GISSELBRECHT C,BRIèRE J,et al.All aggressive lymphoma subtypes do not share similar outcome after front-line auto-transplantation:a matched-control analysis by the Groupe d'Etude des Lymphomes de l’Adulte(GELA) [J].Ann Oncol,2004,15: 1790-1797.
[4]	[KG*1]GLASS B,KLOESS M,BENTZ M,et al.Dose-escalated CHOP plus Etoposide (Mega-CHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high risk non-Hodgkin lymphoma[J].Blood,2006,107: 3058-3064.
[5]	[KG*1]YANO S,ASAI O,DOBASHI N,et al.Long-term follow-up of autologous stem cell transplantation for patients with aggressive non-Hodgkin lymphoma who had bone marrow involvement at initial diagnosis in the pre-rituximab era[J].Clin Lymphoma Myeloma,2007,7: 361-363.
[6]	[KG*1]CHEN A I,MCMILLAN A,NEGRIN R S,et al.Long-term results of autologous hematopoietic cell transplantation for penpherM T cell lymphoma: the Stanford experience[J].Biol Blood Marrow Transplant,2008,14: 741-747.
[7]	[KG*1]ZINZANI P L.High-dose therapy and stem cell transplantation[J].Semin Hematol,2010,47 Suppl 1: S15-17.
[8]	[KG*1]YANG D H,KIM W S,KIM S,et al.Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphonm,unspecified:complete remission at transplantation and the prognostic index of the peripheral T cell lymphoma are the major factors predictive of outcome [J].Biol Blood Marrow Transplant,2009,15:118-125.
[9]	[KG*1]FEYLER S,PRINCE H M,PEARCE R,et al.The role of high dose thinapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study[J].Bone Marrow Transplant,2007,40: 443-450.
[10]	卜庆,黄慧强,林旭滨,等.侵袭性T细胞性非霍奇金淋巴瘤自体造血干细胞移植后长期随访结果[J].中山大学学报(医学科学版),2009,30(3):352-356.
[11]	LE-GOUILL S,MOREAU P,MORINEAU N,et al.Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or replased high grade non-Hodgking lympoma with poor prognosis factors: a prospective pilot study[J].Haematologica,2002,87: 333-334.
[12]	罗依,黄河,蔡真,等.双次自体外周血干细胞移植联合序贯大剂量CHOEP方案治疗中高度恶性淋巴瘤[J].中国实验血液学杂志,2005,13(4):628-630.
[13]	黄文荣,达万明,张伯龙,等.自体外周血与骨髓造血干／祖细胞双次移植的并发症[J].中国实验血液学杂志,2005,13(1):30-34.
[14]	VAN IMHOFF G W,VAN DER HOLT B,MACKENZIE M A,et al.Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem cell transplantation as first-line treatment in poor-risk,aggressive non-Hodgkin’s lymphoma: Comparative analysis of Duch-Belgian hematoncology cooperative group studies 27 and 40[J].J Clin Oncol,2005,23: 3793-3801.